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Strategies to improve the viability of steatotic livers could reduce the risk of dysfunction after surgery and increase the number of
organs suitable for transplantation. Peroxisome proliferator-activated receptors (PPARs) are major regulators of lipid metabolism
and inﬂammation. In this paper, we review the PPAR signaling pathways and present some of their lesser-known functions in
liver regeneration. Potential therapies based on PPAR regulation will be discussed. The data suggest that further investigations are
required to elucidate whether PPAR could be a potential therapeutic target in liver surgery and to determine the most eﬀective
therapies that selectively regulate PPAR with minor side eﬀects.
1.Introduction
Liver transplantation has evolved as the therapy of choice for
patients with end-stage liver disease. However, the waiting
list for liver transplantation is growing at a rapid pace,
whereas the number of available organs is not increasing
proportionately. The potential use of steatotic livers, one of
the most common types of organs in marginal donors, for
transplantation has become a major focus of investigation.
However, steatotic livers are more susceptible to ischemia-
reperfusion (I/R) injury, and the transplantation of steatotic
levels results in a poorer outcome than that of nonsteatotic
livers. Indeed, the use of steatotic livers for transplantation
is associated with an increased risk of primary nonfunction
or dysfunction after surgery [1, 2]. In hepatic resections,
the operative mortality associated with steatosis exceeds
14%, compared with 2% for healthy livers, and the risks of
dysfunction after surgery are similarly higher [2, 3]. Despite
advances aimed at reducing the incidence of hepatic I/R
injury (summarized in earlier reviews) [1, 2], the results to
dateareinconclusive.Inthispaper,wereviewtheperoxisome
proliferator-activated receptor alpha (PPARα)a n dP P A R γ
signaling pathways in steatosis, inﬂammation and regener-
ation, three key factors in steatotic liver surgery [1–5]. Our
review of the diﬀerent strategies pursued to regulate PPAR
in liver diseases may motivate researchersto develop eﬀective
treatmentsforsteatoticliversinpatientsundergoingI/R.The
potential clinical application of strategies that regulate PPAR
in the setting of steatotic liver surgery is also discussed.
2.CharacteristicsofPPAR
PPARs belong to the hormone nuclear receptor superfamily
and consist of three isoforms: PPARα,P P A R γ,a n dP P A R β/δ.
Of these, our group and others have demonstrated that
PPARα and PPARγ are important regulators of postischemic
liver injury [1, 2, 6, 7] that exert their eﬀects on steatosis and
inﬂammation, which is inherent in steatotic liver surgery [8–
12].
Previous results indicate that the presence of fatty inﬁl-
tration by itself in the liver (without any surgical interven-
tion) does not induce changes in PPARα or PPARγ levels,
as no diﬀerences were observed in the levels of these tran-
scription factors between steatotic and nonsteatotic livers of2 PPAR Research
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Figure 1: Basic mechanism of PPAR action. Receptor X retinoide,
RXR; PPAR-response element, PPER.
a sham group of Zucker rats [13, 14]. These results contrast
reports from the literature indicating high or low PPARγ
levels in steatotic livers compared with those in nonsteatotic
livers [15, 16]. These diﬀerent results can be explained, at
least in part, by diﬀerences in the level of PPARγ regulation
between rats and mice [17], the diﬀerent obesity experimen-
talmodelsevaluated,andthedegreeofsteatosis.Wereported
that PPARγ expression levels in nonsteatotic livers during
liver transplantation were similar to those observed in the
sham group. However, increased PPARγ levels were observed
in steatotic liver grafts [14, 18]. Thus, steatotic liver grafts
are more predisposed to overexpress PPARγ.T h i si si nl i n e
with clinical studies, in which PPARγ was upregulated in the
livers of obese patients with nonalcoholic fatty liver disease
(NALFD) [19]. Additionally, diﬀerences in PPARα expres-
sion were observed among diﬀerent liver types. Indeed,
steatoticliversaremorepredisposedtodownregulatePPARα,
when they are subjected to warm hepatic ischemia [13]. In
linewiththeseﬁndings,PPARαisdownregulatedinthelivers
of obese patients with NALFD [20]. Findings such as these
must be considered when applying the same pharmacologi-
cal strategies indiscriminately to patients with steatotic and
nonsteatotic livers because the eﬀects may be very diﬀerent.
PPARs can both activate and inhibit gene expression by
twomechanisms:transactivationandtransrepression.Trans-
activation is DNA- and ligand-dependent. PPARs activate
transcription in a ligand-dependent manner by binding
directly to speciﬁc PPAR response elements (PPREs) in
target genes as heterodimers with retinoid X receptor
(RXR). Agonist binding leads to the recruitment of coac-
tivator complexes that modify the structure of chromatin
and facilitate the assembly of the general transcriptional
machinery at the promoter [21]. Transrepression is ligand-
dependent and may explain the anti-inﬂammatory actions
of PPARs [22]. PPARs repress transcription by antagonizing
the actions of other transcription factors [21] (see Figure 1).
Physiologically,PPAR-RXRheterodimersmaybindtoPPREs
in the absence of a ligand. Although the transcriptional
activation depends on the ligand-bound PPAR-RXR, the
presence of unliganded PPAR-RXR at a PPRE has eﬀects
that vary depending on the promoter context and cell type
[22]. Further investigations on the structures of PPARs and
the mechanisms by which PPARs regulate gene transcription
may be useful for designing certain strategies, such as the use
of PPAR antagonists or agonists. As shown in the following
sections,thecurrentlyusedpharmacologicalstrategiesaimed
at regulating PPAR could not be incorporated into liver
surgery due to their potential side eﬀects.
Given the antiobesity and anti-inﬂammatory properties
of PPARα and PPARγ [8–12], pharmacological interventions
targeting these transcription factors could be a promising
strategy to treat hepatic steatosis in patients undergoing I/R.
However, as shown in Figure 1, the eﬀects of pharmacologi-
calstrategiesaimedatmodulatingPPARsdependonthetype
of ischemia (cold or warm ischemia), the length of ischemia,
and the type of the liver (nonsteatotic or steatotic liver).
3. Effect of PPAR on Hepatic I/R
To the best of our knowledge, few studies have examined
both the I/R-inducedexpression of hepatic PPARα and the
potential beneﬁts of PPARα agonists under these conditions.
According to previous studies by our group, PPARα mRNA
and protein levels in nonsteatotic livers during I/R were
similar to those of the sham group, and PPARα did not
play a crucial role in I/R injury in nonsteatotic livers [13].
This contrasts studies published by Okaya and Lentsch [23]
and Xu et al. [24], who reported the beneﬁts of PPARα
agonists in postischemic liver injury. The protective eﬀects
were possibly associated with reductions in neutrophil accu-
mulation, oxidative stress, and tumor necrosis factor (TNF)
and interleukin-1 (IL-1) expression (Figure 2). Although the
doseandpretreatmenttimeofthePPARαagonistWY-14,643
were similar in both studies, Okaya and Lentsch [23]a n dX u
et al. [24], reported an ischemic period of 90min [23, 24];
ourischemicperiodwas60min,whichistheischemicperiod
currently used in liver surgery [13]. Thus, 60min of ischemia
appears insuﬃcient for inducing changes in PPARα levels in
nonsteatotic livers. In nonalcoholic steatohepatitis (NASH)
and simple steatosis, treatment of mice with the PPAR acti-
vator Wy-14,643 protects steatotic livers against I/R injury,
and the beneﬁts of this treatment potentially occur through
the dampening of adhesion molecule and cytokine responses
and activation of nuclear factor kappa B (NF-κB) and IL-
6p r o d u c t i o n[ 25]. In steatotic livers undergoing warm
ischemia, PPARα agonists can limit the damage induced by
I/R.PPARαagonistsaswellasischemicpreconditioning(PC)
through PPARα inhibited mitogen-activated protein kinases
(MAPK) expression following I/R (Figure 2). This in turn
inhibited adiponectin accumulation in steatotic livers and
adiponectin worsening eﬀects on oxidative stress and hepatic
injury [13]. Given these data, PPARα regulation could be an
alternative method for reducing the greater oxidative stress
incurred by steatotic livers. Indeed, preventing I/R injury in
steatotic livers via therapies aimed at inhibiting reactive oxy-
gen species (ROS) production has proven diﬃcult. Steatotic
livers might produce SOD/catalase-insensitive ROS, whichPPAR Research 3
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Figure 2: PPAR and hepatic I/R injury. Angiotensin II, Ang II; epidermal growth factor, EGF; insulin-like growth factor, IGF; interleukin-
6, IL-6; mitogen-activated protein kinases, MAPKs; nuclear factor kappa B, NFκB; PPARα agonist; pioglitazone, peroxisome proliferator-
activated receptors, PPAR; ischemic preconditioning, PC; retinol binding protein, RBP4, PPARα agonist; Wy-14,643.
maybeinvolvedinthemechanismoffailureofsteatoticlivers
after transplantation [26]. Moreover, gene therapy based on
antioxidant overexpression is limited by the toxicity of the
vectors [2, 27]. In a recent study of nonsteatotic livers under-
going warm hepatic ischemia, the dietary supplementation
with n-3 polyunsaturated fatty acids (PUFAs) increased
hepatic n-3 PUFA content and reduced hepatic n-6/n-3
PUFA content. This was associated with PPARα upregula-
tion, which in turn reduced NF-κB signaling and oxidative
stress, leading to a reduced inﬂammatory response [28].
The function of PPARγ in hepatic I/R injury is unclear.
Previousresultsinlivertransplantationstudiesindicatedthat
I/R did not induce changes in PPARγ expression in non-
steatotic livers, and consequently, strategies based on PPARγ
regulation had no eﬀect on hepatic injury [14]. These results
were diﬀerent from those observed in nonsteatotic livers
underwarmischemiaconditions[6].Inthatstudy,treatment
with pioglitazone, a PPARγ agonist, signiﬁcantly inhibited
hepatic I/R injury (Figure 2) .T h ep r o t e c t i v ee ﬀect was asso-
ciated with the downregulation of several proinﬂammatory
cytokines and chemokines and neutrophil accumulation [7].
This is in line with other results indicating that PPARγ-
deﬁcient mice displayed more severe injuries than untreated
mice under warm ischemia conditions [6]. Furthermore,
pioglitazone treatment inhibited apoptosis and signiﬁcantly
improvedthesurvivalofmiceinalethalmodelofhepaticI/R
injury [7]. Previous studies indicated that PPARγ activation
inhibits the release of TNFα, IL-1, and IL-6 by macrophages
[29, 30], which could be of interest in steatotic livers. Indeed,
under warm hepatic ischemia, higher IL-1 and lower IL-
10 levels were detected in steatotic livers after reperfusion
thaninnonsteatotic livers[31].This imbalancebetweenpro-
and anti-inﬂammatory ILs increased oxidative stress and
decreased the tolerance of steatotic livers to I/R. In addition,
diﬀerent studies have reported proinﬂammatory and anti-
inﬂammatory roles of TNF-α and IL-6, respectively, in the
vulnerability of steatotic livers undergoing I/R [2, 32].
Previous results indicated that PPARγ activation in
hepatocytes by rosiglitazone treatment increases autophagy
and protects against hepatic I/R injury. Autophagy is4 PPAR Research
an evolutionarily conserved cellular process for recycling of
old proteins and organelles via the lysosomal degradation
[33]. Thus, these results suggest that PPARγ has anti-inﬂam-
matory properties and therefore may be relevant during hep-
atic I/R injury. In line with these data, PPARγ upregulation
is a key mechanism of the beneﬁts of diﬀerent pharmaco-
l o g i c a lo rs u r g i c a ls t r a t e g i e sf o rs t e a t o t i cl i v e r su n d e r g o i n g
I/R. Thus, some results based on isolated perfused livers
indicated that the addition of growth factors (epidermal
growth factor (EGF) and insulin-like growth factor-1 (IGF-
I)) to University of Wisconsin (UW) preservation solution
protected steatotic livers due to PPARγ overexpression [34].
Similarly, EGF pretreatment mediated by PPARγ overexpres-
sion protected steatotic livers undergoing warm ischemia
[35]( Figure 2). Moreover, in warm hepatic ischemia, PPARγ
upregulationwasakeymechanismofthebeneﬁtsofpharma-
cological blockers of angiotensin II (angiotensin-converting-
enzyme(ACE)inhibitorsandAngIIreceptorantagonists)on
steatotic livers [36]. However, the role of PPARγ in hepatic
I/R injury could depend on the surgical conditions, as a
recent study of liver transplantation indicated that treatment
with a PPARγ antagonist was eﬀective in steatotic livers,
suggesting a detrimental role of PPARγ under these condi-
tions [14]. In line with this ﬁnding, PPARγ inhibition was
a key mechanism of the beneﬁts of RBP4 treatment and
PC on steatotic liver grafts [14]. Considering these results,
drugstargetingPPARγregulationcanpotentiallyincreasethe
number of organs suitable for transplantation, as these drugs
can improve the outcome for marginal grafts that would
not otherwise have been transplanted. However, the data
on PPARγ reported in steatotic liver transplantation models
with standard liver graft sizes should not be extrapolated
to small-size steatotic liver grafts. In the case of small liver
transplants, the liver regeneration inherent in this surgical
procedure and the mechanism of hepatic damage derived
from the removal of hepatic mass should be considered
[1, 31, 36]. In small liver grafts the periods of ischemia
ranged 40–60min, whereas the periods of ischemia ranged
6–8 hours for cadaveric donor liver transplantation.
4. Effect of PPAR on Hepatic Steatosis
Numerous studies suggest that the actions of PPARα can
prevent steatosis. Mice deﬁcient in PPARα develop hepatic
steatosis when fasted or fed a high-fat diet [37, 46, 57].
Treatment with a PPARα agonist decreased hepatic steatosis
in mice on a methionine- and choline-deﬁcient (MCD) diet
[37]. Activation of PPARα by the agonist Wy-14,643 amelio-
rated alcoholic fatty liver- and MCD-induced steatohepatitis
[37, 38]. The critical role of PPARα in ameliorating steatosis
is mediated through the regulation of a wide variety of genes
involved in peroxisomal, mitochondrial, and microsomal
FA β-oxidation systems in the liver [58]. When steatotic
livers are submitted to certain stresses much as partial
hepatectomy, the activation of PPARα by bezaﬁbrate reduces
the availability of FAs from circulation, reducing thus the
hepatic sphingolipid synthesis [40] (see Table 1).
It is well known that n-3 PUFAs and their derivative FAs
activate PPARα [59–61], which then heterodimerizes with
RXR and liver X receptor, leading to the transcription of a
large number of genes involved in lipid metabolism. It has
been reported that n-3 PUFAs are more potent than the
n-6 PUFAs as in vivo activators of PPARα [59]. In addition,
PUFA metabolites such as eicosanoids or oxidized FAs have
one to two orders of magnitude greater aﬃnity for PPARα
and are consequently far more potent transcriptional activa-
tors of PPARα-dependent genes [59].
The interaction of PPARα with its DNA recognition site
is markedly enhanced by ligands such as hypotriglyceridemic
ﬁbrate drugs, conjugated linoleic acid, and PUFAs [59]. The
discovery of PPARα led quickly to the idea that PPARα was
a “master switch” transcription factor that was targeted by
PUFA to coordinately suppress genes encoding lipid synthe-
sis proteins and to induce genes encoding lipid oxidation
proteins [59]. In line with this idea, recent studies suggested
thatn-3FAsserveasimportantmediatorsofgeneexpression,
working via the PPARs to control the expression of the genes
involved in lipid and glucose metabolism and adipogenesis
[61].Neschenetal.[62]demostratedthattheadministration
of dietary ﬁsh oil (n-3) to rats increases the FA capacity
of their livers through its ability to function as a ligand
activator of PPARα and thereby induces the transcription of
several gene-encoding proteins aﬃliated with FA oxidation.
Of interest, other studies examining the eﬀects of ﬁsh oil
feeding on the expression of several genes of PPAR knockout
mice clearly indicated that hepatic gene regulation by ﬁsh
oil feeding involves at least two diﬀerent pathways: PPARα-
dependent and PPARα-independent pathways. Enzymes for
peroxisomal (CYP4A2) and microsomal (AOX) oxidation
are PPARα-dependent and upregulated by ﬁsh oil feeding,
whereas those for lipid synthesis (FAS; S14) are PPARα-
independent and downregulated. This indicates that the FA
regulation of de novo hepatic lipogenesis and FA oxidation
are not mediated through a common factor (e.g., PPARα)
[61].
Given all these data into in account, the regulation of
PPARα by PUFA, particularly n-3 PUFA and possibly conju-
gated linoleic acid, may oﬀer an explanation for the reported
beneﬁts of these FAs in diﬀerent pathologies.
In obese NAFLD patients, the increased production of
ROS leads to the depletion of n-3 PUFAs due to enhanced
lipid peroxidation. As PPARα is activated through direct
binding to n-3 PUFA, liver PPARα function is compromised
in obesity. This prevented the upregulation of genes involved
in lipid transport, FA β-oxidation and thermogenesis, favor-
ing FA and triacylglycerol synthesis over FA β-oxidation and
thus promoting hepatic steatosis [20]. Thus, PPARα acti-
vation by n-3 PUFA supplementation ameliorated hepatic
steatosis in obese NAFLD patients [20]. In line with this,
NASH patients have low levels of circulating n-3 PUFA, with
a consequent increase of the n-6/n-3 FA ratio and impaired
PPARα activity in the liver [42, 43]. NASH patients treated
with eicosapentaenoic acid (EPA) or n-3 PUFAs, a mixture
of EPA and docosahexaenoic acid, exhibited improvements
in hepatic steatosis and necroinﬂammation in humans and
rats with NASH, probably due to the reduction of hepatic
TNFα expression and improvement of insulin sensitivity
[41–43]. Moreover, PUFAs activate PPARα, leading toPPAR Research 5
Table 1: Eﬀect of strategies that regulate PPAR on hepatic injury, steatosis, and regeneration in experimental models and patients. Angiot-
ensin II: Ang II; choline deﬁcient: CD; epidermal growth factor: EGF; high-fat diet: HFD; insulin-like growth factor 1: IGF-1; methionine
choline deﬁcient: MCD; nonalcoholic Steatohepatitis: NASH; peroxisome proliferator-activated receptors: PPARs; polyunsaturated fatty
acids: PUFAs; ischemic preconditioning: PC; retinol binding protein-4: RBP4.
PPARα
PPARα activators
Strategies Time Eﬀect Experimental
model and patients Steatosis and hepatic injury Regeneration
WY-14,643 (30μmol/kg/d) [17]3 w e e k s ↑ PPARα Obese Zucker rats ↑ β-oxidation of fatty acids Not evaluated
WY-14,643 (180μmol/kg/d) [17]1 w e e k ↑ PPARα Ob/ob mice
↑ β-oxidation of fatty acids;
↓ triglycerides Not evaluated
WY-14,643 (10mg/kg) [23, 24] 1hbefore
ischemia
↑ PPARα
Mice or Rats;
warm ischemia
(90min)
↓ hepatic injury Not evaluated
WY-14,643 (10mg/kg) [13] 1hbefore
ischemia
↑ PPARα
Zucker obese rats;
warm ischemia
(60min)
↓ hepatic injury Not evaluated
WY-14,643 (10mg/kg) [25] 10 days before
surgery
↑ PPARα
Foz/foz mice;
steatotic livers;
warm ischemia
(90min)
↓ hepatic injury
↑ cell cycle
entry
Wy-14,643 (0.1%) [37]5 w e e k s ↑ PPARα Mice fed MCD diet ↓ steatohepatitis Not evaluated
Wy-14,643 (0.1%) [38]1 2 d a y s ↑ PPARα Mice fed MCD diet
↓ steatohepatitis;
↑ hepatic fatty acid
oxidation
Not evaluated
Bezaﬁbrate [39]5 w e e k s ↑ PPARα Mice fed MCD
↓ hepatic triglycerides;
↑ hepatic fatty acid
oxidation
Not evaluated
Benzaﬁbrate (75mg/kg) [40]7 d a y s ↑ PPARα
Rats;
partial
hepatectomy
↓ availability of fatty acids;
sphingolipid synthesis
↓ liver
regeneration
PC (5min/10min) [13] Immediately
before ischemia
↑ PPARα
Obese Zucker rats;
warm ischemia
(60min)
↓ hepatic injury Not evaluated
n - 3P U F A( E P A( 2 7 0m g / k g )a n d
DHA (180mg/kg)) [28] 7d a y s ↑ PPARα
Sprague-Dawley
rats;
warm ischemia
↓ hepatic injury,
inﬂammation, and
oxidative stress
Not evaluated
EPA (2700mg/d) [41] 1 year ↑ PPARα NAFLD patients
↓ steatosis, hepatic injury,
necroinﬂammation, and
oxidative stress
Not evaluated
n-3 PUFA (1g/day) [42] 1 year ↑ PPARα NAFLD patients
↓ steatosis, hepatic injury,
and necroinﬂammation Not evaluated
n-3 PUFA (2g/day) [43] 6 months ↑ PPARα NAFLD patients
↓ steatosis, hepatic injury,
necroinﬂammation, and
hepatic injury
Not evaluated
n-3 PUFA (2g, 3 times daily)
[44] 24 weeks ↑ PPARα
NAFLD patients
with
hyperlipidemia
↓ steatosis and hepatic
injury Not evaluated
Ω-3 FA (5mL, thrice daily) [45]2 4 w e e k s ↑ PPARα NAFLD patients
with dyslipidemia
↓ steatosis and hepatic
injury Not evaluated
Atorvastatin (20mg/daily) [45]2 4 w e e k s ↑ PPARα NAFLD patients
with dyslipidemia
↓ steatosis and hepatic
injury Not evaluated
Orlistat (120mg, thrice daily)
[45] 24 weeks ↑ PPARα NAFLD patients
with dyslipidemia
↓ steatosis and hepatic
injury Not evaluated6 PPAR Research
Table 1: Continued.
PPARα knockout
Strategies Time Eﬀect Experimental model Steatosis and hepatic
injury Regeneration
PPARα-knockout [23]— ↓ PPARα
PPARα-null mice
Warm ischemia
(90min)
↑ hepatic injury Not evaluated
PPARα-knockout [46]— ↓ PPARα PPARα-null mice fed
HF diet
↑ hepatic β-oxidation Not evaluated
PPARα-knockout [47]— ↓ PPARα PPARα-null mice
Partial hepatectomy Not evaluated
↓ liver
regeneration
PPARγ
PPARγ activator
Strategies Time Eﬀect Experimental model Steatosis and hepatic
injury Regeneration
Rosiglitazone (10mg/kg) [6] 30min before
ischemia
↑ PPARγ PPARγ± mice ↓ hepatic injury Not evaluated
Rosiglitazone (2.5μmol/kg/d)
[17] 1w e e k ↑ PPARγ Ob/ob mice ↓ triglycerides Not evaluated
Rosiglitazone (3mg/kg/day) [48]5 w e e k s ↑ PPARγ PPARγﬂ/ﬂ mice fed
HFD diet
↑ steatosis Not evaluated
Rosiglitazone (1mg/kg/day) [49]1 2 w e e k s ↑ PPARγ Obese C57BL/6J mice ↑ steatosis Not evaluated
Rosiglitazone (10mg/kg) [50] 2d a y sb e f o r e
surgery
↑ PPARγ Mice partial
hepatectomy Not evaluated
↓ hepatic
regeneration
Troglitazone (0.1%) + adPPARγ
[51]
adPPARγ (5th day)
troglitazone (5 days)
↑ PPARγ PPARα-null mice fed
CD diet
↑ steatosis Not evaluated
Pioglitazone (500μg/Kg) [52]8 w e e k s ↑ PPARγ Rat fed liquid diet +
alcohol
↓ liver injury Not evaluated
Pioglitazone (30mg) [53]9 6 w e e k s ↑ PPARγ Patients with NASH ↓ steatosis Not evaluated
Pioglitazone (25mg/kg/day) [54] 5d a y sb e f o r e
surgery
↑ PPARγ KK-AY, mice
partial hepatectomy Not evaluated
↑ hepatic
regeneration
Pioglitazone (20mg/kg) [7] 1.5h before
ischemia
↑ PPARγ
Mice
Warm ischemia
(60min)
↓ hepatic injury Not evaluated
Ang II blockers
Captopril (100mg/kg) or
PD123319 (30mg/kg) [36]
Immediately before
ischemia
↑ PPARγ
Obese Zucker rats;
warm ischemia
(60min)
↓ hepatic injury Not evaluated
EGF and IGF-1 (10μg/L) [34]2 4 h i n U W s o l u t i o n ↑ PPARγ
Obese Zucker rats;
isolated liver perfused
(24h cold ischemia)
↓ hepatic injury Not evaluated
EGF (100μg/Kg) [35]
3d o s e s( e v e r y8h )
starting before
surgery
↑ PPARγ
Obese Zucker rats;
warm ischemia
(60min)
↓ hepatic injury Not evaluated
IGF-I (400μg/Kg) [35]
2d o s e s( e v e r y1 2h )
starting before
surgery
↑ PPARγ
Obese Zucker rats;
warm ischemia
(60min)
↓ hepatic injury Not evaluated
Adenovirus PPARγ +
rosiglitazone (50mg/kg/day)
[55]
8w e e k s ↑ PPARγ C57BL/6J mice fed
MCD diet
↓ steatohepatitis and
ﬁbrosis Not evaluated
PC (5min/10min) [36] Immediately before
ischemia
↑ PPARγ
Obese Zucker rats;
warm ischemia
(60min)
↓ hepatic injury Not evaluatedPPAR Research 7
Table 1: Continued.
PPARγ inhibitor
Strategy Time Eﬀect Experimental model Steatosis and hepatic
injury Regeneration
GW9662 (1mg/kg) [14]1 h b e f o r e s u r g e r y ↓ PPARγ Liver transplantation
(6h cold ischemia)
Does not change in
hepatic injury Not evaluated
GW9662 (1mg/kg) [14]1 h b e f o r e s u r g e r y ↓ PPARγ
Steatotic liver
transplantation (6h cold
ischemia)
↓ hepatic injury Not evaluated
GW9662 (1mg/kg, 3
times/week) [55] 8w e e k s ↓ PPARγ C57BL/6J mice fed MCD
diet
↑ steatohepatitis,
ﬁbrosis and hepatic
injury
Not evaluated
RBP4 (150μg/kg) [14] 30min before surgery ↓ PPARγ
Steatotic liver
transplantation (6h cold
ischemia)
↓ hepatic injury Not evaluated
PC (5min/10min) [14] Immediately before
ischemia
↓ PPARγ
Steatotic liver
transplantation (6h of
cold ischemia)
↓ hepatic injury Not evaluated
PPARγ inhibitor
Strategies Time Eﬀect Experimental model Steatosis and hepatic
injury Regeneration
PPARγ-knockout [56]— ↓ PPARγ Liver-speciﬁc
PPARγ-null mice
↓ steatosis Not evaluated
increased FA β-oxidation; hence, they can shift the energy
balance from storage to consumption [41, 43]. n-3 PUFAs
have also been proved as safe and eﬃcacious for patients
with NAFLD associated with hyperlipidemia, as indicated
by reduced hepatic damage and serum lipid levels [44]. In
another study, the eﬃcacy and safety of three hypolipidemic,
agents in patients with NAFLD with dyslipidemia were eval-
uated. In this context, predominantly hypertriglyceridemic,
hypercholesterolemic, and overweight patients were treated
with n-3 FAs, atorvastatin, and orlistat, respectively. The
three diﬀerent groups of patients exhibited reduced hepatic
damage, normalized of hepatic steatosis, and reduced serum
lipids [45].
Considering that steatosis is a risk factor in liver surgery,
strategies aimed to reduce steatosis could increase the toler-
ance of steatotic livers to I/R. There is considerable evidence
that liver regeneration is impaired in certain genetic models
in which the liver contains excess fat. For example, steatotic
livers from Ob mice exhibit defective liver regeneration and
high mortality following partial hepatectomy [63]. Similarly,
impaired liver regeneration was observed in steatotic livers
undergoing partial hepatectomy under vascular occlusion
compared with that in nonsteatotic livers [31]. On the
contrary, drugs that reduce hepatic steatosis, such as PPARα
regulators, should be considered with caution in clinical liver
surgery, as other studies indicate that genetic or pharmaco-
logic approaches that reduce lipid accumulation may also
hinderliverregeneration[63–66].Thus,aquestionistowhat
degree should we reduce steatosis in steatotic livers to protect
this type of liver. Another question is whether we should
reduce steatosis before the surgical procedure and therefore
avoidthevulnerabilityofsteatoticliverstoI/R,orincontrast,
should we use drugs aimed at reducing hepatic triglycerides
during surgery and thus conserve the energy required for
liver regeneration. Moreover, research evaluating whether
the short-term administration of PPARα agonists might
alleviate hepatic steatosis in steatotic livers before I/R would
be of interest for clinical practice because there are obvious
diﬃculties concerning the feasibility of long-term PPARα
agonist administration in some I/R processes, in particular
liver transplantation from cadaveric donors, because this is
an emergency procedure in which there is very little time to
pretreat the donor with PPARα agonists.
Several studies attribute a causal role to PPARγ in the
development of steatosis by mechanisms involving the acti-
vation of lipogenic genes and de novo lipogenesis [48, 51].
In accordance, targeted deletion of PPARγ in hepatocytes
protects mice against diet-induced hepatic steatosis [67],
suggesting a prosteatotic role of PPARγ. Similarly, mice
with liver-speciﬁc PPARγ silencing are protected against
hepatic steatosis [56]. Additionally, treatment of ob/ob mice
with rosiglitazone increased liver steatosis [49]. By contrast,
diﬀerent results have been reported regarding the eﬀect
of PPARγ on hepatic steatosis. Indeed, PPARγ-deﬁcient
mice develop more severe MCD-induced NAFLD, whereas
adenovirus-mediated PPARγ overexpression attenuated the
progression of NASH [55]. In line with this ﬁnding,
rosiglitazone treatment prevented the development of NASH
in a model of MCD-treated mice [55], and similar results
were obtained using the PPARγ agonist pioglitazone [52,
53]. These diﬀerent results can be partially explained by
diﬀerences in the studies such as the species, type of PPAR
agonist, method to induce hepatic steatosis, the type of
genetic strategy used to induce PPARγ overexpression or
deﬁciency in PPARγ expression as well as diﬀerences in the
pretreatment times of the drugs used (see Table 1).8 PPAR Research
5. Effect of PPAR on Hepatic Regeneration
Recent studies demostrated that liver regeneration is im-
paired in a number of animal models of fatty liver disease
[68–73]. PPARα-null mice subjected to partial hepatectomy
(PH) have an impaired ability to regenerate hepatic mass.
Emerging evidence suggests that PPARα is a critical mod-
ulator of the energy ﬂux important for the repair of liver
damage. For example, hepatocytes in the periportal regions,
which divide and replicate after PH, require mitochondrial
oxidation of FAs to generate energy [74]. PPARα controls the
constitutive expression of genes involved in mitochondrial
FAoxidation, including carnitine palmitoyltransferase-1[46,
75]. In mice deﬁcient in PPARα, the impaired hepatic regen-
eration is also associated with the altered expression of genes
involved in cell cycle control and cytokine signaling. Studies
with PPARα agonists indicate that PPARα upregulates genes
involved in the cycle cell (Ccnd1 and cMyc) as well as IL1r1
and IL-6r [76]( Figure 3).
It is well known that PPARα aﬀects the transcription of a
number of genes involved in lipid turnover and peroxisomal
and mitochondrial β-oxidation, resulting in the generation
of ATP, which is required to “fuel” liver repair and regener-
ation [76]. By contrast, in conditions in which PPARα func-
tionand/orexpressionisalteredsuchashepaticsteatosis,and
small-size liver grafts, FA metabolism is deviated toward the
accumulation of inadequately metabolized fat, favoring ROS
generation. Consequently, ATP production is decreased, and
the demise of hepatocytes via necrotic cell death is increased,
halting liver repair [77]( Figure 3). Accordingly, mice with
targeted PPARα disruption exhibit increased inﬂammation
and necrosis and delayed liver regeneration following partial
hepatectomy [47].
Previous results indicate that the impaired liver regener-
ation of steatotic rats was partially due to PPARα downreg-
ulation through the AdipoR2 axis. The inhibition of PPARα
signaling, increased triglyceride (TG) accumulation in hepa-
tocytes and inhibited the expression of hepatic enzymes that
contribute to FA oxidation (Figure 3). This was associated
with increased lipid peroxidation and decreased antioxidant
levels [78].
In contrast with the aforementioned data indicating the
beneﬁcial eﬀects of PPARα on hepatic regeneration, a recent
report indicated that PPARα activation by bezaﬁbrate had
negativeeﬀectsonliverregeneration,whichcanbeattributed
to the inhibition of de novo sphingolipid synthesis [40]. Pre-
sumably, bezaﬁbrate aﬀects de novo sphingolipid synthesis
by decreasing FA availability (Figure 3). The activation of
PPARα by bezaﬁbrate virtually obliterated the postoperative
increase in plasma nonesteriﬁed FAs induced by PH. This
can be explained by the inhibition of hormone-sensitive
lipase activity in adipose tissue by PPARα ligands and their
anti-inﬂammatory properties, which decrease the release
of cytokines such as TNF and IL-6. Both events inhibited
lipolysis in isolated white adipocytes, resulting in reduced FA
release from extrahepatic sources after PH [40].
PPARγ activity is likely to be regulated during normal
liverregeneration,andthedisruptionofthisregulationcould
impair the regenerative response. Pioglitazone improved
hepatic regeneration failure in obese mice. This eﬀect was
associated with reduced TNFα and IL-6 levels. Additionally,
pioglitazone prevented the increased mRNA expression of
signal transducer and activators of transcription-3 phospho-
rylationandsuppressorofcytokinesignaling-3mRNAinthe
l i v e r so fo b e s em i c e[ 54]. However, inconsistent results have
been obtained regarding the eﬀect of PPARγ of liver regen-
eration. Indeed, rosiglitazone inhibited hepatocyte prolifer-
ation in mice undergoing partial hepatectomy by reducing
p38 and cyclin expression [50] (see Figure 3).
On the basis of the inconsistent results reported to date
on the role of PPAR in hepatic regeneration, it is diﬃcult
to discern whether we should attempt to inhibit PPAR or
administer PPAR activators to promote liver regeneration in
surgery.
6. Modulatorsof PPAR inClinicalPractice
Based on the data reported in experimental models (as
reviewed above), diﬀerent strategies (which have been sum-
marized in Table 1)c o u l de x e r te ﬀects on steatosis, inﬂam-
mation, or regeneration by regulating PPAR. Whether these
pharmacological approaches can be translated into treat-
ments for clinical liver surgery remains unknown. For
example,thiazolidinediones(TZDs)shouldnotbeappliedin
clinical liver surgery due to their potential side eﬀects. TZDs
(pioglitazone, troglitazone, and rosiglitazone) are synthetic
PPARγ agonists that are widely used as antidiabetic agents
[79–81]. However, prolonged treatment of obese and dia-
betic mice with TZDs resulted in the development of severe
steatosis, which can lead to steatohepatitis and/or ﬁbrosis.
Troglitazone administration was associated with the devel-
opment of idiosyncratic acute liver failure and was therefore
withdrawn from clinical use [82, 83]. Hepatotoxicity has
subsequently been reported in patients taking pioglitazone
and rosiglitazone [83, 84]. These data provide support for
current clinical practices in which these drugs are avoided or
used judiciously in patients with known or suspected liver
disease. Further experiments should be initiated to devise a
pharmaceutical form appropriate for clinical use.
PPARα agonists are clinically and functionally relevant
as ﬁbrate therapeutics against hyperlipidemia and agents for
reducing the complications of peripheral vascular disease
in diabetic patients [85]. Despite their potentially beneﬁcial
roles,PPARαagonistsshouldbeusedjudiciously.Short-term
administration in humans (1–10 days) would be unlikely
to produce permanent genotoxic eﬀects. However, long-
term exposure to these drugs, which would be required to
reducehepaticsteatosis,canresultinoxidativeDNAdamage,
among other eﬀects [86–90]( Figure 4).
Further studies will also be required to elucidate whether
growthfactors,AngIIblockers,orRBP4maybesaferprotec-
tive pharmacologic strategies for regulating PPAR in hepatic
I/R injury in clinical practice (Figure 4). Nevertheless, none
of the aforementioned strategies is speciﬁc for PPAR.
To avoid the potential side eﬀects of PPAR agonists,
strategies that regulate PPARα, such as the induction of PC
could be of clinical interest. PC is an adaptive mechanism
that consists of a brief period of I/R, resulting in markedPPAR Research 9
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resistance in the liver, prior to a subsequent prolonged
ischemic stress. Our successes regarding the eﬃcacy of PC in
nonsteatotic and steatotic livers undergoing warm ischemia
(associated with PH) and liver transplantation [1, 2, 14, 91–
93] have resulted in the clinical application of PC.
S ev e ra ls t u d i e sh a v ed e m o n s tra t e dt h ee ﬀectiveness of PC
in the resection of steatotic and nonsteatotic livers in clinical
practice [94–96]. In such studies, the authors primarily
performedliverresectionviaacontinuousPringlemaneuver.
However, other data indicate that PC does not improve
postoperative liver function and does not aﬀect morbidity
or mortality after hepatectomy under vascular exclusion of
the liver with the preservation of caval ﬂow [97, 98]. The
discrepancy between these diﬀerential eﬀects of PC during
hepatic resection might have arisen from the absence of
back ﬂow perfusion of the liver during vascular exclusion
compared with that during the Pringle maneuver, which
involves interruptions only to the inﬂow to the liver. In
addition, the ischemic period used by Azoulay et al. [97]w a s
longer (10min on average) that that used by Clavien et al.
[94]. All of these could explain, at least partially, the diﬀerent
eﬀectiveness of PC in the clinical practice of liver surgery.
In the past decade, serious eﬀorts have commenced to
translate some of the robust beneﬁts of PC against ischemia
reperfusion to liver transplantation in clinical practice. It
is fair to conclude that the overall clinical results have
been less impressive than the observations in experimental
animals. There are diﬀerent data on the eﬀectiveness of PC
in I/R injury associated with liver transplantation [99–102].
However, these diﬀerential eﬀects cannot be explained by the
useofPCperiodsthathaveprovedexperimentallyineﬀective
or by the clinical use of diﬀerent cold ischemic times
from those evaluated experimentally. However, the reduced
proportionofsubjectswithsteatosisenrolledinPCtrialsand
the presence of brain death in clinical liver transplantation,
which has thus far been evaluated in experimental studies of
liver transplantation, should be considered.
Aspreviouslymentioned,theproportionofsubjectswith
steatosis who have been enrolled in PC trials to date has
been small (10%). Thus, in the future, clinical trials must
make serious eﬀorts to include a larger proportion of donor
with steatotic livers to clarify the eﬀectiveness of PC in
liver transplantation in clinical practice. The beneﬁts of PC
are more likely to become clinically meaningful in patient10 PPAR Research
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groups with an increased risk of morbidity and mortality
following PH, that is, in patients with hepatic steatosis and
cirrhosis. Infact,in thelargestprospective randomized study
of PC in PH, Clavien et al. [94, 103] demostrated that
PC was more eﬀective in reducing reperfusion injury in
patients with steatotic livers. Furthermore, Li et al. [104]
reported that PC decreased the risk of hepatic insuﬃciency
and shortened the hospital stay in patients with cirrhosis
who underwent PH. There is the remote possibility that PC
may not be eﬀective in the context of brain death. Deceased
organ donors have hemodynamic instability with decreased
mean arterial pressure, portal venous, and hepatic tissue
bloodﬂow.Furthermore,braindeathinducesamultifaceted,
intense systemic inﬂammatory response that is manifested
in many organs, including the liver. It is very likely that
suchaframeworkofinﬂammatoryresponse,wellentrenched
before the induction of PC, would interact with the various
mechanistic aspects of PC and modulate the eventual PC
response. To our knowledge, there are no studies of PC in the
liversinbrain-deadanimals.Additionalexperimentalstudies
of PC of the liver and other organs in brain-dead animals are
needed to ﬁll the knowledge gaps. The clinical observations
suggest that PC alone may be insuﬃcient to provide easily
demonstrable clinical beneﬁts in the presence of brain death.
In that context, PC may be more eﬀective when combined
with physical, chemical, and pharmacological PC methods.
Suchexperimentalinvestigationscouldaddressanimportant
clinical problem in liver transplantation, as more than 80%
of livers used for transplantation are taken from cadaveric
donorsandapproximately20%ofallbrain-deaddonorshave
a mild-to-moderate hepatic steatosis [105].
7. Conclusions and Perspectives
The use of experimental models has contributed to a better
understanding of the multifaceted roles of PPARs. Strategies
b a s e do nP P A Rr e g u l a t i o nh a v et h ep o t e n t i a lt oi m p r o v e
the postoperative outcomes of patients undergoing hepatic
resections and to increase the number of organs suitable
for transplantation, as these strategies may improve the out-
comes of patients receiving marginal grafts that would not
otherwise have been transplanted, leading to new possibil-
ities for small steatotic liver transplants. Before a complete
deﬁnition of a successful therapeutic strategy based on PPAR
regulation is formed, several additional points need to be
addressed. Comparative studies of the roles of diﬀerent
PPAR isoforms in hepatic I/R are required. We recently
mapped the eﬀects of PPAR on the pathways involved in the
inﬂammatory process and lipid metabolism, and the eﬀects
of PPAR diﬀer according the experimental model used.
Therefore, therapeutic strategies targeting PPAR regulation
also diﬀer according to the surgical procedure. Moreover, the
responseofdiﬀerenttypesoflivertoPPARstimulationmight
diﬀer and involve diﬀerent signal transduction pathways that
are at present marginally understood. Further research is
required to select drugs that regulate PPAR with minimal
side eﬀects and optimize such potential treatments (e.g.,
dose and pharmacokinetics) before being translated intoPPAR Research 11
treatments for human disease. Pharmacological strategies
that speciﬁcally regulate PPAR including ﬁbrates and TZDs
might be inappropriate for clinical liver surgery due to their
potential side eﬀects. Conversely, surgical strategies such as
PC have been applied in clinical surgery; however, these
strategies do not exert their eﬀects exclusively on PPAR, as
theyaﬀectmultipleaspectsofI/Rinjury.Onlyafullappraisal
oftheroleofPPARinhepaticI/Randstudiesonthestructure
of this transcription factor will permit the design of new
protective strategies for clinical liver surgery based on the
speciﬁc regulation of PPAR without adverse eﬀects.
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